80 related articles for article (PubMed ID: 25752515)
1. β-Arrestin2 Contributes to Cell Viability and Proliferation via the Down-Regulation of FOXO1 in Castration-Resistant Prostate Cancer.
Duan X; Kong Z; Liu Y; Zeng Z; Li S; Wu W; Ji W; Yang B; Zhao Z; Zeng G
J Cell Physiol; 2015 Oct; 230(10):2371-81. PubMed ID: 25752515
[TBL] [Abstract][Full Text] [Related]
2. Arrestin2 modulates androgen receptor activation.
Purayil HT; Zhang Y; Dey A; Gersey Z; Espana-Serrano L; Daaka Y
Oncogene; 2015 Jun; 34(24):3144-51. PubMed ID: 25109335
[TBL] [Abstract][Full Text] [Related]
3. A transcription-independent function of FOXO1 in inhibition of androgen-independent activation of the androgen receptor in prostate cancer cells.
Liu P; Li S; Gan L; Kao TP; Huang H
Cancer Res; 2008 Dec; 68(24):10290-9. PubMed ID: 19074897
[TBL] [Abstract][Full Text] [Related]
4. Platelet-Synthesized Testosterone in Men with Prostate Cancer Induces Androgen Receptor Signaling.
Zaslavsky AB; Gloeckner-Kalousek A; Adams M; Putluri N; Venghatakrishnan H; Li H; Morgan TM; Feng FY; Tewari M; Sreekumar A; Palapattu GS
Neoplasia; 2015 Jun; 17(6):490-6. PubMed ID: 26152357
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor co-regulatory networks in castration-resistant prostate cancer.
Sung YY; Cheung E
Endocr Relat Cancer; 2014 Feb; 21(1):R1-R11. PubMed ID: 24152433
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
7. Modulation of androgen receptor by FOXA1 and FOXO1 factors in prostate cancer.
Zhao Y; Tindall DJ; Huang H
Int J Biol Sci; 2014; 10(6):614-9. PubMed ID: 24948874
[TBL] [Abstract][Full Text] [Related]
8. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Martin SK; Kyprianou N
Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
[TBL] [Abstract][Full Text] [Related]
9. Resveratrol inhibits hypoxia-inducible factor-1α-mediated androgen receptor signaling and represses tumor progression in castration-resistant prostate cancer.
Mitani T; Harada N; Tanimori S; Nakano Y; Inui H; Yamaji R
J Nutr Sci Vitaminol (Tokyo); 2014; 60(4):276-82. PubMed ID: 25297617
[TBL] [Abstract][Full Text] [Related]
10. Nucleoporin 62 and Ca(2+)/calmodulin dependent kinase kinase 2 regulate androgen receptor activity in castrate resistant prostate cancer cells.
Karacosta LG; Kuroski LA; Hofmann WA; Azabdaftari G; Mastri M; Gocher AM; Dai S; Hoste AJ; Edelman AM
Prostate; 2016 Feb; 76(3):294-306. PubMed ID: 26552607
[TBL] [Abstract][Full Text] [Related]
11. [The concept and mechanisms of castration-resistant prostate cancer].
Naito S; Shiota M
Nihon Rinsho; 2014 Dec; 72(12):2090-4. PubMed ID: 25518339
[TBL] [Abstract][Full Text] [Related]
12. β-arrestin2 mediates β-2 adrenergic receptor signaling inducing prostate cancer cell progression.
Zhang P; He X; Tan J; Zhou X; Zou L
Oncol Rep; 2011 Dec; 26(6):1471-7. PubMed ID: 21833475
[TBL] [Abstract][Full Text] [Related]
13. PDLIM2 suppression efficiently reduces tumor growth and invasiveness of human castration-resistant prostate cancer-like cells.
Kang M; Lee KH; Lee HS; Park YH; Jeong CW; Ku JH; Kim HH; Kwak C
Prostate; 2016 Feb; 76(3):273-85. PubMed ID: 26499308
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor 1/insulin signaling activates androgen signaling through direct interactions of Foxo1 with androgen receptor.
Fan W; Yanase T; Morinaga H; Okabe T; Nomura M; Daitoku H; Fukamizu A; Kato S; Takayanagi R; Nawata H
J Biol Chem; 2007 Mar; 282(10):7329-38. PubMed ID: 17202144
[TBL] [Abstract][Full Text] [Related]
15. FOXO1 binds to the TAU5 motif and inhibits constitutively active androgen receptor splice variants.
Bohrer LR; Liu P; Zhong J; Pan Y; Angstman J; Brand LJ; Dehm SM; Huang H
Prostate; 2013 Jul; 73(10):1017-27. PubMed ID: 23389878
[TBL] [Abstract][Full Text] [Related]
16. Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer.
McGrath MJ; Binge LC; Sriratana A; Wang H; Robinson PA; Pook D; Fedele CG; Brown S; Dyson JM; Cottle DL; Cowling BS; Niranjan B; Risbridger GP; Mitchell CA
Cancer Res; 2013 Aug; 73(16):5066-79. PubMed ID: 23801747
[TBL] [Abstract][Full Text] [Related]
17. Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression.
Shiota M; Takeuchi A; Song Y; Yokomizo A; Kashiwagi E; Uchiumi T; Kuroiwa K; Tatsugami K; Fujimoto N; Oda Y; Naito S
Endocr Relat Cancer; 2011 Aug; 18(4):505-17. PubMed ID: 21652770
[TBL] [Abstract][Full Text] [Related]
18. MHY-449, a novel dihydrobenzofuro[4,5-b][1,8] naphthyridin-6-one derivative, induces apoptotic cell death through modulation of Akt/FoxO1 and ERK signaling in PC3 human prostate cancer cells.
Lee SH; Kang YJ; Sung B; Kim DH; Lim HS; Kim HR; Kim SJ; Yoon JH; Moon HR; Chung HY; Kim ND
Int J Oncol; 2014 Mar; 44(3):905-11. PubMed ID: 24424889
[TBL] [Abstract][Full Text] [Related]
19. Insulin-Like Growth Factor-1 Contributes to Mucosal Repair by β-Arrestin2-Mediated Extracellular Signal-Related Kinase Signaling in Experimental Colitis.
Chen T; Zheng F; Tao J; Tan S; Zeng L; Peng X; Wu B
Am J Pathol; 2015 Sep; 185(9):2441-53. PubMed ID: 26362717
[TBL] [Abstract][Full Text] [Related]
20. Hydrazinobenzoylcurcumin inhibits androgen receptor activity and growth of castration-resistant prostate cancer in mice.
Wu M; Kim SH; Datta I; Levin A; Dyson G; Li J; Kaypee S; Swamy MM; Gupta N; Kwon HJ; Menon M; Kundu TK; Reddy GP
Oncotarget; 2015 Mar; 6(8):6136-50. PubMed ID: 25704883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
